


Incidental Findings Are Critical to Breast Cancer Diagnosis

Insights from Lifepoint Health's enterprise roll-out across 53 facilities



Most breast cancer early detection programs are built around guideline-driven screening, which remains essential. However, data from Lifepoint's deployment of Eon Breast challenge conventional assumptions about how breast cancer is detected, and which patients may require the most urgent follow-up. Patients with incidental breast abnormalities are not a secondary concern — they represent a clinically urgent, often overlooked population requiring timely intervention.

6.2X

higher likelihood of cancer diagnosis from incidental findings

34%

higher rate of being clinically high-risk at initial exam

>50%

of incidental cancer diagnoses occurred in patients ineligible for routine screening

Three Barriers Limiting Breast Program Scale

Incidental breast findings are identified but inconsistently managed

Breast abnormalities identified outside screening workflows often rely on manual follow-up processes, making coordination difficult and introducing variability in patient management.

Operational inefficiencies limit program capacity

Technologists spend significant time on patient and provider communications, stuffing and mailing letters, MQSA-compliance documentation, and follow-up tracking. These activities limit available appointment slots and constrain program growth.

Multi-site variability compounds challenges

Across health systems, disconnected tools and siloed workflows across facilities create fragmented visibility and limited interoperability — making it difficult to track patients across facilities, ensure consistent compliance, and scale programs effectively



Patients with incidental findings represent a clinically distinct population where diagnostic urgency is often higher. These findings reinforce that extending workflows beyond screening pathways is essential to improving follow-up consistency and earlier detection.



How Eon Breast Changes the Model

Eon Breast **unifies screening and incidental findings into a centralized and standardized workflow** that identifies, tracks, and manages all patients requiring breast care. Powered by condition-specific clinical AI and **supported by embedded Eon Breast Care Navigators**, the platform brings fragmented processes into a single system of action.

Eon Breast Care Navigators Expand Clinical Capacity

Embedded Breast Navigators act as an extension of the local teams, managing patient communication, follow-up coordination, and documentation activities that traditionally fall on mammography technologists. By embedding MQSA compliance directly into Eon's automated workflows, Eon Breast helps restore staff time and increase capacity without adding headcount.

Lifepoint Health: Scaling Breast Care System-Wide

BEFORE IMPLEMENTATION

- 53 distinct breast programs with independent workflows
- Manual tracking across spreadsheets and local tools
- Limited ability to scale follow-up management

AFTER IMPLEMENTATION

CLINICAL IMPACT & PROGRAM GROWTH

1 in 8

net-new breast patients identified through **incidental findings**

256

cancers diagnosed across screening and incidental pathways

2.7x

increase in completed downstream exams per month

51%

of incidental cancers diagnosed in patients ineligible for screening

OPERATIONAL CAPACITY

4 hours

per week of annual staff capacity restored per site

Mammography appointment times reduced from **30 min → 15 minutes**

+42K

average letters automated per month by Eon Breast

+32K

average calls led per month by Eon Breast Care Navigators

The Result

Unifying workflows and reducing administrative burden enabled Lifepoint to expand access, improve follow-up consistency, and scale breast care delivery across its national footprint.

To learn more about Eon Breast or request a briefing, visit www.eonhealth.com

These results reflect outcomes from patients newly identified and managed over time after implementing Eon Breast across 53 facilities in 19 states between March 2023 and October 2025. ©2026 Eon. All rights reserved.